HER2-Positive Breast Cancer: Clinical Advances to Overcome Unmet Patient Needs

1.00 CME
$0 FEE
HER2-Positive Breast Cancer: Clinical Advances to Overcome Unmet Patient Needs


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an educational grant from Daiichi Sankyo, Inc. 

Activity Description

Approximately 25% of all breast cancer cases are human epidermal growth factor receptor 2-positive (HER2+). Compared to HER2- tumors, HER2+ breast cancers are a more aggressive subtype that demonstrate poorer response to standard chemotherapy. Targeted treatment options have demonstrated substantial improvements to clinical outcomes, yet many patients treated with HER2-targeted therapies eventually experience disease progression due to the development of acquired resistance. Recently approved and emerging targeted therapies for HER2+ metastatic breast cancer have demonstrated the potential to enhance patient outcomes when incorporated into existing clinical treatment algorithms. In this continuing medical education activity, experts in the field examine the persisting unmet needs for patients who are treated with first-line agents for the management of HER2+ metastatic breast cancer and evaluate the latest clinical evidence regarding new treatment options for patients with HER2+ breast cancer who have progressed on the current standards of care.

Target Audience

The intended audience for this activity is hematologist-oncologists, oncologists, nurses, physician assistants, and other health care professionals involved in the management of patients with HER2-postive breast cancer.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Examine persisting unmet needs for patients who are treated with first-line agents for the management of HER2-positive metastatic breast cancer.
  • Evaluate the latest clinical evidence regarding treatment options for patients with HER2-postiive breast cancer who have progressed on current standards of care.

Activity Chair

Joyce O’Shaughnessy, MD
Celebrating Women Chair in Breast Cancer Research
Director, Breast Cancer Research Program
Baylor University Medical Center
Dallas, TX


Shanu Modi, MD
Associate Professor
Weill Cornell Medical College
Associate Attending
Section Head, HER2 Breast Cancer Program
Memorial Sloan Kettering Cancer Center
New York, NY


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For the purpose of recertifying with ANCC, AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME can be used.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 1.0 hours credit for completing this program.

This enduring material is approved for 1 year from the date of original release, June 26, 2020, through June 25, 2021.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 3 out of 4 of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Faculty reports the following relationship(s)

Shanu Modi, MD
Consulting Fee: AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, MacroGenics, Seattle Genetics
Speakers Bureau: AstraZeneca, Daiichi Sankyo, Genentech, Seattle Genetics
Contracted Research: AstraZeneca, Daiichi Sankyo, Genentech, Novartis, Seattle Genetics

Joyce O'Shaughnessy, MD
Consulting Fee: AbbVie, Agendia, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Eisai, Genentech, Genomic Health, GRAIL, Heron Therapeutics, Immunomedics, Ipsen, Jounce Therapeutics, Lilly, Merck, Myriad, Novartis, Odonate Therapeutics, Pfizer, prIME Oncology, Puma Biotechnology, Roche, Seattle Genetics, Syndax, Takeda

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at cme@vindicoCME.com